

W10: Causes and Co-morbidities of Nocturia

Workshop Chair: An-Sofie Goessaert, Belgium 12 September 2017 09:00 - 10:30

Start	End	Topic	Speakers
09:00	09:20	Phenotyping Nocturia – Judge a Book by its Cover?	An-Sofie Goessaert
09:20	09:40	Sleep and Nocturia – Central Mechanisms into Business?	Karlien Dhondt
09:40	10:00	Bladder and Kidney – Making the Bladder Gladder or Lowering	Philip Van Kerrebroeck
		the Water Levels?	
10:00	10:20	Questionnaire on Nocturia – to TANGO or Not to TANGO?	Wendy Bower
10:20	10:30	Questions	All

Speaker Powerpoint Slides

Please note that where authorised by the speaker all PowerPoint slides presented at the workshop will be made available after the meeting via the ICS website www.ics.org/2017/programme Please do not film or photograph the slides during the workshop as this is distracting for the speakers.

Aims of Workshop

Nocturia is a highly prevalent condition affecting both men and women of all ages. It is no longer a problem merely attributed to overactive bladder or benign prostate hyperplasia. There can be an impairment in one or more factors of the triad brain-kidney-bladder but also other factors such as obesity, hypertension, peripheral edema, sleep disturbance, depression, medication, etc can play a role.

The objective of this workshop is to provide an overview on causes and co-morbidities of nocturia and how to identify them.

Learning Objectives

This workshop should allow the attendant to know the answers to following questions:

- What physical features can help you to identify possible causes or co-morbidities of nocturia?
- 2. How does sleep affect nocturia and how does nocturia affect sleep?
- 3. What not to miss in the work-up of nocturia?

Learning Outcomes

After this course the attendant should be aware of the most evident causes and co-morbidities of nocturia and he/she should be able to identify them in patients in clinical practice.

Target Audience

Urologists, Gynaecologists, Geriatricians and Nurses

Advanced/Basic

Basic

1. **Speaker 1: Phenotyping nocturia – judge a book by its cover? -** An-Sofie Goessaert, urology trainee, Ghent University Hospital Belgium

Nocturia is a complaint which seems to be invisible for anyone else but for the patient and for his or her bed partner, unless the patient is asked about it or mentions it him or herself. However, there are certain physical uitingen that can help you understand or suspect the underlying pathophysiology. It is obvious that you need a full medical history to get a direction on the pathophysiology, for example, the presence of kidney disease, diabetes, depression, etc., conditions that are also not necessarily clinically visible. But looking at your patient and examining your patient is as important for a good diagnostic workout.

What to do on a first consultation?

- Blood pressure > arterial hypertension?
- Weight assessment / waist circumference > obesity?
- Cardiovascular examination (shortness of breath, chronic coughing or wheezing, peripheral edema, confusion or impaired thinking, high heart rate) > cardiac failure?
- Digital rectal examination > benign prostate hypertrophy?

A few examples:

- Obesity:

Obesity is a multifactorial disease with adverse health consequences, such as cardiovascular disease, type 2 diabetes, hypertension, sleep apnea, and possibly depression, which may result independently in nocturia.

Lifestyle-related factors may also be more common among the obese. It is possible that nocturia in some obese persons is related to excessive nighttime eating or drinking, especially consumption of alcohol. This can cause nocturnal polyuria, leading to an increased nighttime voiding frequency.¹

- Arterial hypertension:

The link between hypertension and NP can be explained by its stimulating effect on glomerular filtration, inhibiting effect on the ADH and its effect on the pressure-natriuresis relation in the kidney. This is a feedback system to control blood pressure, whereby increases in renal perfusion pressure lead to a decrease in sodium reabsorption and more sodium excretion. ²⁻⁴ Healthy adults show a nighttime drop in blood pressure of at least 10%, however this is lacking in people with non-dipping hypertension, who show an enhanced sodium excretion. ³ Such non-dipping hypertension has been linked to physical activity during nighttime, which supports the finding that non-dipping hypertension is more prevalent in patients who wake up to go to the toilet at night. ²

- Peripheral edema:

Peripheral edema are common in patients with venous insufficiency, heart failure, hypertension and autonomic dysfunction. These patients typically accumulate fluid in their lower extremities while standing during daytime, but when they change to the supine position when going to sleep in the evening, this fluid is reabsorbed into the circulation. This present as a surplus of fluid to the circulatory system, which stimulates ANP and glomerular filtration and results in more nighttime urine production. 5,6

- 1. Aoki Y., Yokoyama O. Metabolic Syndrome and nocturia. LUTS. 2012; 4 (s1): 11-15.
- 2. Feldstein CA. Nocturia in arterial hypertension: a prevalent, underreported, and sometimes underestimated association. J Am Soc Hypertens. 2013;7(1):75-84.
- 3. McKeigue PM, Reynard JM. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet. 2000;355(9202):486-8.
- 4. Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons with nocturia and nocturnal polyuria. Neth J Med. 2002:60(7):276-80.
- 5. Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease. Bju International. 2011;107(5):702-13.
- 6. Boongird S, Shah N, Nolin TD, Unruh ML. Nocturia and aging: diagnosis and treatment. Adv Chronic Kidney Dis. 2010;17(4):e27-40.

2. **Speaker 2: Sleep and nocturia – central mechanisms into business?** – Karlien Dhondt, Ghent University Hospital Belgium

The aim of this talk is to demonstrate some interesting aspects on nocturia by focussing on sleep. More specifically, sleep fragmentation and dopaminergic neurotransmission. Before going into detail, we start with a few aspects about sleep physiology first.

When studying sleep, one has to bear in mind that sleep phsylology is influenced by two important factors, which are known as the circadian rhythm, and the sleep homeostasis. In this context, there is a range of neurotransmittors that are or sleep or wake promoting. The circadian rhythm is the hour glass in which we can sleep, it is independent from the previous nights. On the contrary, the sleep homeostasis is based on how we slept the nights before and reflects sleep pressure that has been built up during the day.

Research of sleep and uro/nephrology in our University Center, started in pediatrics. We explored sleep by performing a full polysomnography in children with therapy resistant or dependent nocturnal enuresis (NE). The observations were tantalizing: we found increased cortical arousals (sleep fragmentation) associated with periodic limb movements (PLMS). This was later confirmed in a case control study. Later, the study was repeated in a homogenous group of children with monosymptomatic NE, and the same observations were found. However, compared to the pilot study in which more children with reduced bladder capacity were included, the PLMS-index was significant higher in the latter group (1).

A population based epidemiological study from Finland comprising a systematic evaluation of factors associated with noctura in aduls reported a correlate between RLS (strongly associated with PLMS in adults) and nocturia (2). One might suspect a persistent common pathophysiological mechanism with: sleep fragmentation, PLMS, NE or nocturia.

The observation of PLMS is of interest. PLMS are a well described feature in sleep medicine, they are seen on a PSG and are periodic short movements of the legs (flexion in the ankel, hip, knee). The pathophysiology of PLMS is caused by a disturbed dopaminergic neurotransmission. However, the cause of dopamine depletion can be variable. In case of dopaminergic

depletion, the effect on motor, sensory nerves and autonomic balance are hypothesized to be less inhibited. Moreover, dopamine has also an important role in the mictury center in the brain.

The second part is the role of sleep fragmentation. The amount of cortical arousals reflects sleep fragmentation and this is known to cause sleep deprivation. The autonomic nerve system with a higher sympathetic output (increased blood pressure, increased heart rhythm)

A good model for explaining how these factors might interact is Parkinson disease.

The final conclusion is that dopaminergic dysfunction might be an important mediating factor in some phenotypes of nocturia and NE. This will be further explored in the future.

- (1) K. Dhondt et al. J Urol, 2009, Acta Paediatr 2014, Ped Nephr 2015
- (2) K. Tikkinen et al. Am J Epidemiol 2009
- 3. **Speaker 3: Bladder and kidney making the bladder gladder or lowering the water levels? –** Philip Van Kerrebroeck, Professor of Urology, Maastricht University Medical Center, the Netherlands

The International Continence Society (ICS) defines nocturia as 'the complaint that the individual has to wake at night one or more times to void...each void is preceded and followed by sleep.' Patients experiencing <2 voids/night in general do not experience significant bother. However bother, as well as morbidity and mortality, will be significant with >2 voids/night. Nocturia is an underreported, underdiagnosed, and undertreated condition, with many patients believing it to be a natural consequence of aging. Nocturia is associated with multiple medical conditions, and conveys an increased mortality risk.

The treatment of nocturia advanced because of the understanding that it is a distinct clinical entity with a number of pathophysiologic causes. Nocturia may be sub classified into three categories, based on the causative mechanisms:

- 1. Reduced Voided Volume, a reduced capacity for the bladder to store urine, whether globally or only during sleep
- 2. Global (or 24 hour) Polyuria, an overabundant production of urine during the diurnal plus nocturnal periods, quantified as a volume of greater than 40 ml/kg in 24 hours
- 3. Nocturnal Polyuria (NP) overabundant production of urine only at night, with 24 hour urine output remaining within the normal range. NP is defined as nocturnal urine production of > 20 % of 24 hour output in younger adults (21–35) and > 33 % of 24 hour urine output in older adults

Traditionally nocturia was believed to be primarily the result of either overactive bladder (OAB) or benign prostatic hyperplasia (BPH). This was seemingly confirmed in the 1990s when the increase in prostate outlet reducing procedures occurred with a concomitant decline in nocturia. However, NP is now recognized as a major etiology of nocturia. Data obtained from cohorts of the NOCTUPUS and US/CANADA trials, indicated that the majority of nocturia patients were found to have nocturnal polyuria. The NOCTUPUS trials were three randomized controlled trials studying the effect of desmopressin tablet formulation on subjects with nocturia. Upon enrollment, subjects completed 7-day frequency volume charts (FVC) recording the volume and time of their voids. Examining this data, it was found that the NP prevalence in records included in analysis (641/846) was 76 %. If the FVCs discarded from analysis due to incompletion were assumed not have nighttime polyuria, the proportion with NP was 64 % (641/1003).

Similarly, the United States/Canada trial was a phase III randomized double blind trial to evaluate efficacy of the treatment of nocturia with desmopressin Melt. This study indicated a NP prevalence in complete records (806/917) of 88 %. If the FVCs discarded from analysis assumed not have nocturnal polyuria, the proportion with NP was 57 % (806/1,412). Subgroup analysis showed increasing prevalence of NP with age, and a slightly higher occurrence in men compared to women. In the young (<65), NP affected 66 % (325/493) in the NOCTUPUS trial and 83 % (390/468) in the US/Canada trial, while the prevalence in patients >65 years old was 90 % (316/353) in the NOCTUPUS trial and 93 % (416/449) in the US/Canada Trial.

4. Speaker 4: Questionnaire on nocturia – to TANGO or not to TANGO? – Wendy Bower, Department of Medicine and Community Care, Melbourne Health and Department of Medicine, Dentistry and Health Science the University of Melbourne.

The causal pathway of nocturia is multi-factorial and differs between patients. There are significant interactions between voiding at night and markers of poor health. A comprehensive multidisciplinary assessment metric that identifies co-existing causes of nocturia beyond the urinary tract was warranted.

This presentation describes the development and use of TANGO a screening tool to target the aetiology of nocturia and guide outcomes. A Cochrane-style review identified variables carrying a significant risk in relation to nocturia severity. Discriminating items in robust tools measuring co-morbidities were collected; pertinent clinical measures were added. After removal of item duplication, the self-completed 57 item questionnaire (TANGO) was piloted (n=22), modified, then completed by 300 patients ≥40 years of age with nocturia who were presenting to the sleep disorder, diabetes, rehabilitation, continence or falls and balance clinics, or in-patients of aged care or rehabilitation wards.


Endorsement of items was analysed; those with a high floor effect (i.e. >70% of responses "never" or its equivalent), an interrelationship >0.8 (i.e. redundant) or >50% missing data were removed. Measures included in their entirety were subject to exploratory factor analysis to identify items with multiple loadings. Psychometric properties were used to reduce the initial TANGO metric to a short form.

Non-urinary tract factors identified on the causal pathway of nocturia clustered into the domains of mental health, cardiovascular, metabolic, sleep and inflammatory conditions and medication. List 1 shows the metrics from which TANGO items were drawn. A medical history checklist was added to the questionnaire along with a clinician-completed section of physical measures (height; weight; neck, waist and hip circumferences; heart rate; blood pressure; TUG Test).

List1: Metrics from which TANGO items were sourced:


- Overactive Bladder Symptom Score
- International Prostate Symptom Score
- Epworth Sleepiness Scale
- Pittsburg Sleep Quality Index
- Insomnia Severity Index
- STOPBang Obstructive Sleep Apnea Questionnaire
- AUSDRISK Diabetes Risk Assessment Tool
- Hospital Anxiety and Depression Scale
- EQ-5D-3L Health Status Questionnaire
- SF-36 Health Status Questionnaire
- Brief Pain Inventory (Short Form)
- Psoriatic Arthritis Screening and Evaluation Questionnaire
- General Practitioner Cognitive Screening Test

The TANGO Short Form was developed from items significantly associated with high frequency nocturia. Patient self-completion required between 30 seconds and 2 minutes. Test-retest reliability of this new metric demonstrated substantial to excellent agreement (Kappa 0.6 to 0.79 and 0.8 to 1.00 respectively). This tool has the potential to improve evaluation across disciplines and medical specialties and to smooth inequalities associated with current care of patients with nocturia.











Start	End	Торіс	Speakers
09:00	09:20	Phenotyping Nocturia – Judge a Book by its Cover?	An-Sofie Goessaert
09:20	09:40	Sleep and Nocturia – Central Mechanisms into Business?	Karlien Dhondt
09:40	10:00	Bladder and Kidney – Making the Bladder Gladder or Lowering the Water Levels?	Philip Van Kerrebroeck
10:00	10:20	Questionnaire on Nocturia – to TANGO or Not to TANGO?	Wendy Bower
10:20	10:30	Questions	All






Workshop 10 – Causes & Co-morbidities of Nocturia

 A shortened version of the handout has been provided on entrance to the hall

 A full handout for all workshops is available via the ICS website.

 Please silence all mobile phones

 Please refrain from taking video and pictures of the speakers and their slides. PDF versions of the slides (where approved) will be made available after the meeting via the ICS website.



An-Sofie Goessaert

Affiliations to disclose†:

Nothing to declare

**Observed to be part that purpose loss will have become separated with topic to the subject, based and furtigener promotion

Funding for speaker to attend:


** Self-funded

Institution (non-industry) funded

Sponsored by:




























An-Sofie Goessaert – Urology Dept., Ghen	t University Hospital, Belgium ICS 2017 FLORENCE				
To continue frequency	To continue frequency volume chart! ¹³				
The obvious	The background				
Reduced bladder capacity	OAB, BPH, bladder stone, bladder cancer				
• 24h polyuria	Diabetes, polydipsia				
Nocturnal polyuria	Impairment ADH, RAAS, ANP				










Sleep and Nocturia - are central mechanisms into business?

ICS Firenze 12th of september 2017 Karlien Dhondt, MD, PhD Center for Neurophysiological Monitoring Ghent University Hospital, Belgium



OUTLINE

- The impact of nocturia on sleep AND wakefullness
- The association of nocturia and sleep disorders
- Potential underlying central mechanisms in nocturia

OUTLINE

- The impact of nocturia on sleep AND wakefullness
- The association of nocturia and sleep disorders
- Potential underlying central mechanisms in nocturia

• Reasons for nocturnal awakenings (US, by age group)



- Nocturia is an independent predictor of insomnia and of deterioration of sleep quality

 difficulties falling back to sleep
 fewer hours of sleep
- Nocturia is known to impair mental functioning, quality of life and productivity
- Patients with two or more voids a night have a higher risk of mortality

• First uninterrupted sleep period (FUSP) Billwise et al. Sleep Med 2015, J Clin Skeep Med 2015

PSQI Variable	First (Shortest) Time to First Void Quartile Mean (SE)	Second Time to First Void Quartile Mean (SE)	Third Time to First Void Quartile Mean (SE)	Fourth (Longest) Time to First Void Quartile Mean (SE)	р
Global Score	9.62 (0.27)	8.54 (0.28)	7.75 (0.28)	7.39 (0.27)	< 0.0001
Quality	1.62 (0.05)	1.57 (0.05)	1.43 (0.05)	1.34 (0.05)	0.0015
Latency	1.70 (0.07)	1.39 (0.07)	1.19 (0.07)	1.11 (0.07)	< 0.0001
Duration	1.16 (0.07)	0.98 (0.07)	0.83 (0.07)	0.80 (0.07)	0.0020
Efficiency	1.50 (0.08)	1.24 (0.08)	1.04 (0.08)	1.10 (0.08)	0.0005
Sleep Disturbance	1.68 (0.05)	1.63 (0.05)	1.54 (0.05)	1.50 (0.05)	0.0358
Sleep Medication	0.73 (0.07)	0.47 (0.07)	0.50 (0.07)	0.50 (0.07)	0.0486
Daytime Dysfunction	1.37 (0.06)	1.26 (0.06)	1.18 (0.06)	1.12 (0.06)	0.0241

When comparing the average PSQI scores among those in the lowest compared to the highest quartile of time to first void, there was a statistically significant difference among all PSQI subscales.


OUTLINE


K. Dho


- The impact of nocturia on sleep AND wakefullness
- The association of nocturia and sleep disorders
 - PLMS in sleep
 - OSAS
- Potential underlying central mechanisms in nocturia

I. Obstructive sleep apnea and nocturia Anconi-Israel et al. Sleep Med Rev. 2015


- Decreased nocturnal plasma renin an aldosterone secretion
- Increase in atrial natriuretic peptide (severe cases)
 - · Nocturnal natriuresis
 - · Increased diuresis
- Treatment with C-pap
 Reverses effects of decreased plasma renin/aldosterone secretion
 - Normalizing sodium output
 - · Normalizing nocturnal diuresis
- · Increase in sleep fragmentation
 - Increase in autonomic arousal
 Sympathetic outflow ++







OUTLINE • The impact of nocturia on sleep AND wakefullness • The association of nocturia and sleep disorders • Potential underlying central mechanisms in nocturia




Dopaminergic neurotransmission


Two types of receptors: D1 like (D1,D5), D2 like (D2,D3,D4)


D1 receptors are more abundant than D2 receptors in neocortical areas, particularly in prefrontal regions

Cortical D1 receptor system plays a key role in executive functioning, working memory, attention, and inhibition, which depends on frontal lobe integrity

Projections:
From the spinal cord perspective (A)
Central brain regions (B)







Causes of dopaminergic hypofunction?

• Genetics

• BTBD9 polymorphism Suplaneasetal N Engl J Med 2007, Moore et al. Steep 2014

• Iron storage


• Circadian disorder (hypothalamus)


• Sleep deprivation (animal studies): decrease of tyrosine hydroxylase


• Aging; loss of dopaminergic neurotransmission

• Human molecular imaging studies have consistently found an age-related decrease of D2 receptor markers in the magnitude of 5–10% per decade, starting in early adulthood habboald et al. Sprang 2009


• Losses of D1 receptor densities in the striatum of around 8% per decade steat Gave 2011





































Are classical BPO treatments good enough?

- Various methods of treating BPO based on assumption that all symptoms caused by prostate problems
 - α-adrenoceptor antagonists
 - 5α-reductase inhibitors
 - TURP
 - Phytotherapy
 - Combination therapy
- These can be effective for some LUTS, but nocturia rated the most bothersome of LUTS - may not be significantly improved1



TURP has limited effect on nocturia

- 118/138 (85.5%) patients with BPO had nocturia before TURP
- After treatment, 91 of these (77.1%) still reported nocturia
- Improvement in nocturia score (1.0) significantly inferior to improvements for all other IPSS symptoms

	Patients scoring ≥2 score before TURP	Patients scoring ≥2 score after TURP	Rate of response (%)
Emptying	102	27	54.3
Voiding frequency	116	63	38.4
Intermittency	101	33	49.3
Urgency	103	70	37.0
Weak stream	122	35	63.0
Hesitancy	84	18	47.8
Nocturia	118	91	19.6

TURP not the answer – are other mechanisms involved?




Tamsulosin OCAS not significantly better than placebo in reducing nocturnal voids

- 8-week study, n=117
- · Some improvements in overall IPSS scores BUT
 - Mean reduction in number of nocturnal voids not significantly greater with tamsulosin OCAS than placebo (p=0.10)
 - Increase in duration of undisturbed sleep not significantly greater with tamsulosin OCAS than placebo (p=0.20)

Maastricht UMC+

Djavan et al. Eur Urol Suppl 2005;4:61-68



Up to 95% of BPE patients have NP and nocturia resistant to $\alpha_1\text{-blocker}$ therapy


- 55/58 patients (95%) with LUTS suggestive of BPE found to have NP
- Of these, 20 received α_1 -blocker therapy for 6 weeks
 - NP unchanged in 75%
 - No significant difference in mean nocturnal urine production before and during therapy


Maastricht UMC+

BPE; benign prostatic enlargeme

Koseoglu et al. J Urol 2005;67:1188–1192

They may benefit similarly from desmopressin treatment for nocturia!






Nocturia needs to be treated according to its causes If a patient has nocturia and diagnosis of OAB or BPO, they may ALSO have NP If NP present, consider combination therapy: Diagnosis Desmopressin Anticholinergic α₁-blocker NP OAB BPO NP + OAB NP + BPO OAB + BPO NP + OAB + BPO

Maastricht UMC+

Conclusions Think on the bladder and the kidneys! >80% of patients with nocturia have nocturnal polyuria (NP) NP comorbid with BPO and/or OAB must be addressed desmopressin successfully treats nocturia caused by NP combination therapy (desmopressin + anticholinergics + α₁-blockers) is feasible to improve nocturia in patients with BPO and/or OAB with NP




Development of TANGO, a screening tool to identify coexisting causes of Nocturia

A/Prof Wendy Bower FACP

Department of Medicine and Community Care, Melbourne Health Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne

The Royal Melbourne Hospital



.. nocturia is outside the category of a storage lower urinary tract symptom (LUTS)

Gulur 2011; Drake 2015

Frequency, Urgency and Nocturia

"...no single variable affected 50% or more of men with nocturia
...in women multiple correlates predictive of night voiding"

Tikkinen 2010


Targeting Aetiology of Nocturia
Guides Outcomes


AIM: To develop a brief patient-completed screening tool to capture all-causes of nocturia

To be used in conjunction with

Bladder diary
Sleep measures
Renal function tests
Urine flow dynamics
Patient-Reported Outcomes








Stage 2: Development of TANGO LF


- Variables having a significant risk association with nocturia of ≥ 1/night identified
- · TANGO Long Form developed
 - 6 domains
 - 57 items. 10 clinical measures
 - self-completed questionnaire
- Sample size: N=250 patients
- ≥ 40 years age, nocturia ≥ 1/night,
- Recruited from Sleep / Continence / Falls and Balance / Rehabilitation services at RMH





TANGO: Methods


Short form:

- Retained items with:
 - Direct causal link to nocturia
 - High endorsement
 - Significant association with nocturia ≥ 2
 - Significant association with high bother
- · Items worded according to cut-off from analysis
- Pilot of Short Form on 10 adults → modification of wording when problematic




































GENDER-SPECIFIC VERSIONS


- Low testosterone levels in men and oestrogen in women is associated with ↑ water and salt diuresis
 - Sex hormones stimulate ANP → to reduce sodium load → \uparrow GFR → \uparrow urine production
- Testosterone deficiency is associated with:
 - Hot flushes and sweating
 - Insomnia or other sleep disturbances
 - Lower sleep efficiency: ↑ nocturnal awakenings, 1 time in slowwave sleep? Modulated via adiposity (Barrett-Connor 2008).
- Low testosterone levels frequently coexist with obstructive sleep apnoea (men)
 - Higher apnea-hypopnea index
 - More sleep time with O₂ saturation levels < 90%.
- Progesterone and estrogen deficiency
 - Difficulty staying asleep
 - Night sweats


GENDER-SPECIFIC VERSIONS


- · TANGO-M extra variables
 - I wake from sleep because of night sweats / feeling hot
 - I wake from sleep because of feeling cold
 - I have not had my testosterone levels checked
- TANGO-F extra variables
 - I have difficulty staying asleep at night because of feeling hot / sweating
 - My last menstrual period was more than 1 year ago
 - I do not take oestrogen (tablets or patches)














TANGO extension • Develop Patient Reported Outcomes from - Sleep - LUTS - QoL - Consumer perspective • Methodology: n=204 data sets that included - Pittsburgh Sleep Quality Index (PSQi), - ICIQ-Overactive Bladder - ICIQ-Female Lower Urinary Tract Symptoms Long Form - ICIQ-Male Lower Urinary Tract Symptoms Long Form - Nocturia Quality of Life • Associations between episode frequency, bother and variables

